Evaluation of anticoagulation in post-surgical patients with mechanical valve replacement
DOI:
https://doi.org/10.55958/jcvd.v19i3.114Keywords:
Valvular Heart Disease, International Normalized Ratio, Mechanical Valve Replacement.Abstract
BACKGROUND: Mitral, aortic, tricuspid, and pulmonary valve disease are the four types of valvular heart disease. Valvular heart disease is defined by damage to or a congenital abnormality in one or more of the heart's valves. Rheumatic heart disease is the term used to describe valvular heart disease that develops as a consequence of rheumatic fever. There have been several suggestions made regarding biomarkers that might be used for tracking the aetiology of aortic valve disease; however, not all biomarkers are candidates that are clinically helpful. Patients who are taking vitamin K antagonists are typically advised to have their blood tested using the international normalised ratio. The purpose of this study was to determine the mean international normalised ratio in patients diagnosed with valvular heart disease who had had mechanical valve replacement and were on anti-coagulant medication.
METHODOLOGY: Between the dates of 28 July 2020 and 28 January 2021, the research was carried out at the Department of Cardiology at the Punjab Institute of Cardiology in Lahore. After the inclusion criteria were satisfied, a total of 250 patients were enrolled. Consent after being fully informed was obtained, as well as demographic information. Then patients underwent surgery. After 3rd month patients were given standard anti-coagulation therapy as per hospital protocol. On each visit, blood sample was taken by using 3cc disposable syringe and sent to the laboratory of the hospital for assessment of INR and serial values of INR.
RESULTS: The mean age of the patients was 42.51±16.59 years, there were 149(59.60%) patients were male. Hypertension and diabetes mellitus was found in 103(41.2%) & 75(30%) patients respectively. After 3rd month the mean INR value of patients was 2.245±0.4016.
CONCLUSION: According to this study the mean international normalized ratio was 2.245±0.4016 with anti-coagulation use after mechanical valve replacement in patients with valvular heart disease
References
Fawzy A, Ali HF, Elanwar M. Mechanical mitral valve prosthesis: Should the INR be above 2 when aspirin is added to the oral anticoagulant? Journal of the Egyptian Society of Cardio-Thoracic Surgery 2017;25(4):285-8.
Fawzy A. Aspirin/warfarin. Reactions 2018;1684:47-13.
Riaz H, Alansari SAR, Khan MS, Riaz T, Raza S, Luni FK, et al. Safety and use of anticoagulation after aortic valve replacement with bioprostheses: a meta-analysis. Circulation: Cardiovascular Quality and Outcomes 2016;9(3):294-302.
Baumgartner H, Falk V, Bax JJ, De Bonis M, Hamm C, Holm PJ, et al. 2017 ESC/EACTS guidelines for the management of valvular heart disease. European heart journal 2017;38(36):2739-91.
Altisent OA-J, Durand E, Muñoz-García AJ, Nombela-Franco L, Cheema A, Kefer J, et al. Warfarin and antiplatelet therapy versus warfarin alone for treating patients with atrial fibrillation undergoing transcatheter aortic valve replacement. JACC: Cardiovascular Interventions 2016;9(16):1706-17.
Iung B, Rodés-Cabau J. The optimal management of anti-thrombotic therapy after valve replacement: certainties and uncertainties. European heart journal 2014;35(42):2942-9.
Mori T, Asano M, Ohtake H, Bitoh A, Sekiguchi S, Matsuo Y, et al. Anticoagulant therapy after prosthetic valve replacement-optimal PT-INR in Japanese patients. Annals of thoracic and cardiovascular surgery 2002;8(2):83-7.
Torella M, Aquila I, Chiodini P, Amarelli C, Romano G, Della Ratta EE, et al. Low-dose anticoagulation after isolated mechanical aortic valve replacement with Liva Nova Bicarbon prosthesis: A post hoc analysis of LOWERING-IT Trial. Scientific reports 2018;8(1):8405.
Ryan F, Byrne S, O’shea S. Randomized controlled trial of supervised patient self?testing of warfarin therapy using an internet?based expert system. Journal of Thrombosis and Haemostasis 2009;7(8):1284-90.
Samsa GP, Matchar DB. Relationship between test frequency and outcomes of anticoagulation: a literature review and commentary with implications for the design of randomized trials of patient self-management. Journal of thrombosis and thrombolysis 2000;9(3):283-92.
Tse H-F, Wang Y-J, Ai-Abdullah MA, Pizarro-Borromeo AB, Chiang C-E, Krittayaphong R, et al. Stroke prevention in atrial fibrillation—an Asian stroke perspective. Heart rhythm 2013;10(7):1082-8.
Zhou X-M, Zhuang W, Hu J-G, Li J-M, Yu J-F, Jiang L. Low-dose anticoagulation in Chinese patients with mechanical heart valves. Asian Cardiovascular and Thoracic Annals 2005;13(4):341-4.
Uetsuka Y, Hosoda S, Aosaki M, Iwade K, Koyanagi H, Ohki K, et al. Clinical significance of thrombotest and PT-INR in monitoring the oral anticoagulant therapy. Japanese Journal of Thrombosis and Hemostasis 1992;3(2):123-30.
Kudo T, Kawase M, Kawada S, Kurosawa H, Koyanagi H, Takeuchi Y, et al. Anticoagulation after valve replacement: a multicenter retrospective study. Artificial organs 1999;23(2):199-203.
Kitamura M, Koyanagi H, Kawada S, Hosoda Y, Kurosawa H, Takeuchi Y, et al. Optimum anticoagulation control after bileaflet mechanical valve replacement: a prospective multi-institutional study. Kyobu geka The Japanese journal of thoracic surgery 1999;52(12):1001-4.
Koertke H, Zittermann A, Wagner O, Ennker J, Saggau W, Sack F-U, et al. Efficacy and safety of very low-dose self-management of oral anticoagulation in patients with mechanical heart valve replacement. The Annals of thoracic surgery 2010;90(5):1487-93.
Misawa Y, Saito T, Konishi H, Oki S-i, Kaminishi Y, Sakano Y, et al. Clinical experience with the Bicarbon heart valve prosthesis. Journal of Cardiothoracic Surgery 2007;2(1):8.
Acar J, Iung B, Boissel JP, Samama MM, Michel PL, Teppe JP, et al. AREVA: multicenter randomized comparison of low-dose versus standard-dose anticoagulation in patients with mechanical prosthetic heart valves. Circulation 1996;94(9):2107-12.
Go AS, Singer DE, Toh S, Cheetham TC, Reichman ME, Graham DJ, et al. Outcomes of dabigatran and warfarin for atrial fibrillation in contemporary practice: a retrospective cohort study. Annals of internal medicine 2017;167(12):845-54.
Yu Z, Ding Y-L, Lu F, Miao L-Y, Shen Z-Y, Ye W-X. Warfarin dosage adjustment strategy in Chinese population. International Journal of Clinical and Experimental Medicine 2015;8(6):9904.
You J, Chan F, Wong R, Cheng G. Is INR between 2.0 and 3.0 the optimal level for Chinese patients on warfarin therapy for moderate?intensity anticoagulation? British journal of clinical pharmacology 2005;59(5):582-7.
Volpp KG, Loewenstein G, Troxel AB, Doshi J, Price M, Laskin M, et al. A test of financial incentives to improve warfarin adherence. BMC health services research. 2008;8(1):1-6.
Larsen TB, Rasmussen LH, Skjøth F, Due KM, Callréus T, Rosenzweig M, et al. Efficacy and safety of dabigatran etexilate and warfarin in “real-world” patients with atrial fibrillation: a prospective nationwide cohort study. Journal of the American College of Cardiology. 2013;61(22):2264-73.
Kamthornthanakarn I, Krittayaphong R. Optimal INR level for warfarin therapy after mechanical mitral valve replacement. BMC cardiovascular disorders 2019;19(1):1-8.
